

# Abdul Rafeh Naqash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1255649/publications.pdf>

Version: 2024-02-01

63  
papers

1,796  
citations

430874

18  
h-index

315739

38  
g-index

64  
all docs

64  
docs citations

64  
times ranked

2305  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	7.1	241
2	Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 551-557.	0.9	235
3	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	1.6	138
4	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
5	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Childâ€“Pugh A and B cirrhosis: A realâ€“world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
6	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3505.	4.1	69
7	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
8	Characterization of KRAS Mutation Subtypes in Nonâ€“small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	4.1	66
9	Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. <i>European Journal of Haematology</i> , 2016, 97, 9-16.	2.2	50
10	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	3.7	47
11	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
12	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	3.7	44
13	Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. <i>Acta OncolÃ³gica</i> , 2018, 57, 705-708.	1.8	43
14	Epigenetics: A primer for clinicians. <i>Blood Reviews</i> , 2016, 30, 285-295.	5.7	42
15	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	2.8	42
16	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3834-3844.	7.0	36
17	Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. <i>Acta OncolÃ³gica</i> , 2018, 57, 867-872.	1.8	33
18	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33

#	ARTICLE	IF	CITATIONS
19	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmunology</i> , 2022, 11, 2017162.	4.6	33
20	Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. , 2019, 7, 169.		28
21	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
22	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Instituteâ€”Cancer Therapy Evaluation Program. <i>Journal of Clinical Oncology</i> , 2022, 40, 3439-3452.	1.6	24
23	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
24	The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1034-1034.	1.7	21
25	Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting. <i>JACC: CardioOncology</i> , 2020, 2, 491-502.	4.0	20
26	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. <i>Oncologist</i> , 2021, 26, e1883-e1886.	3.7	19
27	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. , 2019, 7, 4.		18
28	Differential prognostic effect of systemic inflammation in patients with nonâ€”small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <scp>OAK</scp> trial. <i>Cancer</i> , 2022, 128, 3067-3079.	4.1	15
29	Advances in the management of alveolar soft part sarcoma. <i>Current Problems in Cancer</i> , 2021, 45, 100775.	2.0	14
30	Hemophagocytic lymphohistiocytosis (HLH) secondary to Ehrlichia chaffeensis with bone marrow involvement. <i>Annals of Hematology</i> , 2017, 96, 1755-1758.	1.8	13
31	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
32	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1935-1939.	3.3	8
33	Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Nonâ€”Small-Cell Lung Cancer?. <i>JCO Precision Oncology</i> , 2021, 5, 408-414.	3.0	7
34	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	4.3	7
35	Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. <i>Acta OncolÃ³gica</i> , 2021, 60, 813-817.	1.8	6
36	Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy. <i>Journal of Hepatology</i> , 2020, 73, S40-S41.	3.7	3

#	ARTICLE	IF	CITATIONS
37	Evaluating the utility of pretreatment C-reactive protein (CRP) in survival stratification of advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint blockade (ICB): A prospective cohort study.. Journal of Clinical Oncology, 2018, 36, e15122-e15122.	1.6	3
38	Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. Acta Oncol <sup>3</sup> gica, 2017, 56, 1327-1330.	1.8	2
39	A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome. ACG Case Reports Journal, 2019, 6, e00045.	0.4	2
40	Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.. Journal of Clinical Oncology, 2017, 35, e21712-e21712.	1.6	2
41	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2019, 37, 2577-2577.	1.6	2
42	775â€ŒImmune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. American Journal of Gastroenterology, 2019, 114, S450-S451.	0.4	1
43	Why Are Randomization and Placebos Included in Many Cancer Trials?. JAMA Oncology, 2021, 7, 1080.	7.1	1
44	SIDE in metastatic colon cancer: SEER Database analysis.. Journal of Clinical Oncology, 2018, 36, 753-753.	1.6	1
45	Synchronous brain metastasis and impact of primary tumor side in colorectal cancers.. Journal of Clinical Oncology, 2019, 37, 712-712.	1.6	1
46	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. Journal of Clinical Oncology, 2019, 37, 118-118.	1.6	1
47	A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome. American Journal of Gastroenterology, 2017, 112, S934-S935.	0.4	1
48	Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.. Journal of Clinical Oncology, 2020, 38, e16677-e16677.	1.6	1
49	Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.. Journal of Clinical Oncology, 2022, 40, 9056-9056.	1.6	1
50	Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2022, 40, 8515-8515.	1.6	1
51	1193: CEREBRAL AIR EMBOLISM AFTER CENTRAL VENOUS CATHETER REMOVAL: A CASE SERIES REVIEW. Critical Care Medicine, 2018, 46, 580-580.	0.9	0
52	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	1.6	0
53	Clinical outcomes in very early breast cancer (â‰¥ 1cm): A national population based analysis.. Journal of Clinical Oncology, 2017, 35, e12034-e12034.	1.6	0
54	Survival stratification using a baseline inflammatory physiology based scoring system in advanced non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (anti-PD-1) therapy.. Journal of Clinical Oncology, 2018, 36, 152-152.	1.6	0

#	ARTICLE	IF	CITATIONS
55	National practice pattern and outcome of very early breast cancer.. Journal of Clinical Oncology, 2018, 36, e12530-e12530.	1.6	0
56	Neuroendocrine carcinoma of luminal gastrointestinal tract.. Journal of Clinical Oncology, 2018, 36, e16186-e16186.	1.6	0
57	Abstract 1691: Clinical characteristics influencing survival in stage-IV non-small cell lung cancer treated with nivolumab: A single-institutional experience. , 2018, , .		0
58	Tumor mutational burden (TMB) profile of <i>K-RAS/TP-53</i> co-mutation in metastatic non-small cell lung cancer (m-NSCLC).. Journal of Clinical Oncology, 2019, 37, 2626-2626.	1.6	0
59	Immune checkpoint inhibitorâ€“induced diabetes mellitus across NCI trials.. Journal of Clinical Oncology, 2022, 40, 2668-2668.	1.6	0
60	Age-associated differences in transcriptional expression and tumor immune microenvironment composition among older patients with cancer.. Journal of Clinical Oncology, 2022, 40, 2633-2633.	1.6	0
61	Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.. Journal of Clinical Oncology, 2022, 40, 2508-2508.	1.6	0
62	First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3157-TPS3157.	1.6	0
63	Pan-cancer (ca) analysis of the safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) living with HIV (PLWH): Results from the international CATCH-IT consortium.. Journal of Clinical Oncology, 2022, 40, 2649-2649.	1.6	0